Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The TFAM-OGG1 axis mediates T-2 toxin-induced chondrocyte mitochondrial dysfunction and cartilage degeneration.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2026
Same author

The emergence of the language system in the toddler brain.

bioRxiv : the preprint server for biology·2026
Same author

Antifungal Properties and Genomic Analysis of <i>Burkholderia pyrrocinia</i> DLL-114, an Endophyte of Camphor Tree.

Plant disease·2026
Same author

Functional Magnetic Resonance Imaging in Awake Infants: Insights From More Than 750 Scanning Sessions.

Infancy : the official journal of the International Society on Infant Studies·2026
Same author

Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling.

Cell death & disease·2026
Same author

Latent class analysis of quality of life among patients with Kashin-Beck disease and its association with health literacy and social support.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025

相关实验视频

Updated: Sep 9, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K

通过打破ROS-炎症的积极反来治疗心脏衰竭的双重向纳米催化剂

Haoyu Du1,2, Dinghu Ma1,2, Xiaoyuan Zhang1,2

  • 1Huiya Hospital of The First Affiliated Hospital of Sun Yat-sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Huizhou, 516081, P. R. China.

Advanced healthcare materials
|September 5, 2025
PubMed
概括

这项研究介绍了FUTA,一种用于心力衰竭的新型双纳米催化剂. 在HF模型中,FUTA表现出强大的抗氧化和免疫调节作用,改善心脏功能和减少纤维化.

关键词:
针对心力衰竭免疫调节磁性纳米催化剂氧化应激清理酸功能化

更多相关视频

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K

相关实验视频

Last Updated: Sep 9, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K

科学领域:

  • 生物材料科学
  • 心血管研究
  • 纳米医学

背景情况:

  • 由于氧化应激和免疫失衡, 心脏衰竭 (HF) 是全球性的健康挑战.
  • 目前的HF疗法缺乏心脏特异性,由于心脏输液迅速,有效性受到限制.
  • 制定有针对性的策略对于有效的HF治疗至关重要.

研究的目的:

  • 开发一种双目标纳米催化剂 (FUTA),用于增强心力衰竭治疗.
  • 在体外和体内研究FUTA的抗氧化和免疫调节能力.
  • 评估FUTA在改善心脏结构和功能的治疗潜力.

主要方法:

  • 用酸 (TA) 功能化Fe3O4@UiO-66以产生FUTA.
  • 在体外评估FUTA的激素清除和ROS缓解特性.
  • 在体内评估FUTA对心脏的向,抗氧化作用以及使用磁吸引和TA- ECM结合对心脏功能和纤维化的影响.

主要成果:

  • 在实验室中,FUTA表现出强烈的自由基和活性氧物种 (ROS) 清除.
  • 在实验室中,FUTA恢复了线粒体膜潜力,并减少了心肌细胞缩.
  • 在体内研究显示,FUTA在受伤的心肌中选择性积累,导致心脏结构和功能改善,纤维化减少.

结论:

  • 在心力衰竭方面,FUTA具有显著的治疗潜力.
  • 纳米催化剂有效向心脏组织,并具有协同的抗氧化和免疫调节作用.
  • 通过调节新陈代谢和免疫路径, FUTA 提供了一种有前途的基于材料的心力衰竭治疗策略.